|
1
|
Zhang D and Fan D: Multidrug resistance in
gastric cancer: recent research advances and ongoing therapeutic
challenges. Expert Rev Anticancer Ther. 7:1369–1378. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hu WH, Pendergast JS, Mo XM, Brambilla R,
Bracchi-Ricard V, Li F, Walters WM, Blits B, He L, Schaal SM, et
al: NIBP, a novel NIK and IKK(beta)-binding protein that enhances
NF(kappa)B activation. J Biol Chem. 280:29233–29241. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zong M, Satoh A, Yu MK, Siu KY, Ng WY,
Chan HC, Tanner JA and Yu S: TRAPPC9 mediates the interaction
between p150Glued and COPII vesicles at the target
membrane. PLoS One. 7:e299952012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Bitner D, Filho Pontes AA, Li F,
Liu S, Wang H, Yang F, Adhikari S, Gordon J, Srinivasan S and Hu W:
Expression and function of NIK- and IKK2-binding protein (NIBP) in
mouse enteric nervous system. Neurogastroenterol Motil. 26:77–97.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaiopoulos AG, Athanasoula KC and
Papavassiliou AG: NF-kappaB in colorectal cancer. J Mol Med.
91:1029–1037. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu C, Qin M, Tan L, Liu S and Huang J:
NIBP impacts on the expression of E-cadherin, CD44 and vimentin in
colon cancer via the NF-κB pathway. Mol Med Rep. 13:5379–5385.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan L, Liu SQ, Qin MB, et al: Relationship
between expression of NIBP and noncanonical NF-κB signaling:
Clinical significance in colon carcinoma. World Chin J Diges.
23:1238–1246. 2015. View Article : Google Scholar
|
|
9
|
Zhang Y, Liu S, Wang H, Yang W, Li F, Yang
F, Yu D, Ramsey FV, Tuszyski GP and Hu W: Elevated NIBP/TRAPPC9
mediates tumorigenesis of cancer cells through NF-κB signaling.
Oncotarget. 6:6160–6178. 2015.PubMed/NCBI
|
|
10
|
Thiery JP, Acloque H, Huang RYJ and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shang Y, Cai X and Fan D: Roles of
epithelial-mesenchymal transition in cancer drug resistance. Curr
Cancer Drug Targets. 13:915–929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Y, Guan Z, Liang L, Cheng Y, Zhou J,
Li J and Xu Y: NF-kappaB signaling plays irreplaceable roles in
cisplatin-induced bladder cancer chemoresistance and tumor
progression. Int J Oncol. 48:225–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao YB, Liu SQ, Tan L, Zhou Q and Huang
JA: EGb761 enhances cisplatin and etoposide-induced apoptosis of
human gastric cancer SGC-7901 cells. World Chin J Diges.
21:3330–3337. 2013. View Article : Google Scholar
|
|
15
|
Soltanian S and Matin MM: Cancer stem
cells and cancer therapy. Tumour Biol. 32:425–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weng CC, Kuo KK, Su HT, Hsiao PJ, Chen YW,
Wu DC, Hung WC and Cheng KH: Pancreatic tumor progression
associated with CD133 overexpression: Involvement of increased TERT
expression and epidermal growth factor receptor-dependent Akt
activation. Pancreas. 45:443–457. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nomura A, Banerjee S, Chugh R, Dudeja V,
Yamamoto M, Vickers SM and Saluja AK: CD133 initiates tumors,
induces epithelial-mesenchymal transition and increases metastasis
in pancreatic cancer. Oncotarget. 6:8313–8322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu YM, Li XF, Liu H and Wu XL:
Ultrasound-targeted microbubble destruction-mediated downregulation
of CD133 inhibits epithelial-mesenchymal transition, stemness and
migratory ability of liver cancer stem cells. Oncol Rep.
34:2977–2986. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakuma Y, Yamazaki Y, Nakamura Y,
Yoshihara M, Matsukuma S, Koizume S and Miyagi Y: NF-κB signaling
is activated and confers resistance to apoptosis in
three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
Biochem Biophys Res Commun. 423:667–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zou W, Ma X, Hua W, Chen B and Cai G:
Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian
cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB
pathway. Oncol Rep. 34:3256–3263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang D, Duan H, Huang H, Tong X, Han Y,
Ru G, Qu L, Shou C and Zhao Z: Cisplatin resistance in gastric
cancer cells is associated with HER2 upregulation-induced
epithelial-mesenchymal transition. Sci Rep. 6:205022016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang K, Jiao X, Liu X, Zhang B, Wang J,
Wang Q, Tao Y and Zhang D: Knockdown of snail sensitizes pancreatic
cancer cells to chemotherapeutic agents and irradiation. Int J Mol
Sci. 11:4891–4902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu W, Yang JL, Wang YL, Wang H, Yao M,
Wang L, Gu JJ, Cai Y, Shi Y and Yao DF: Reversal of multidrug
resistance of hepatocellular carcinoma cells by metformin through
inhibiting NF-κB gene transcription. World J Hepatol. 8:985–993.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X,
Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The
AKT1/NF-kappaB/Notch1/PTEN axis has an important role in
chemoresistance of gastric cancer cells. Cell Death Dis.
4:e8472013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T,
Thiery JP and Mori S: Epithelial-mesenchymal status renders
differential responses to cisplatin in ovarian cancer. Oncogene.
34:1899–1907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jia ZF, Wu YH, Cao DH, Cao XY, Jiang J and
Zhou BS: Polymorphisms of cancer stem cell marker gene CD133
are associated with susceptibility and prognosis of gastric cancer.
Future Oncol. 13:979–989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moon YH, Kim D, Sohn HM and Lim W: Effect
of CD133 overexpression on the epithelial-to-mesenchymal transition
in oral cancer cell lines. Clin Exp Metastasis. 33:487–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding Q, Yoshimitsu M, Kuwahata T, Maeda K,
Hayashi T, Obara T, Miyazaki Y, Matsubara S, Natsugoe S and Takao
S: Establishment of a highly migratory subclone reveals that CD133
contributes to migration and invasion through
epithelial-mesenchymal transition in pancreatic cancer. Hum Cell.
25:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tu Z, Xie S, Xiong M, Liu Y, Yang X, Tembo
KM, Huang J, Hu W, Huang X, Pan S, et al: CXCR4 is involved in
CD133-induced EMT in non-small cell lung cancer. Int J Oncol.
50:505–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
